Search

Your search keyword '"Hasford, J."' showing total 711 results

Search Constraints

Start Over You searched for: Author "Hasford, J." Remove constraint Author: "Hasford, J."
711 results on '"Hasford, J."'

Search Results

3. Treatment and outcome of 2904 CML patients from the EUTOS population-based registry

7. Begriffsbestimmungen

8. Methoden

9. Forschungsziele

10. Arzneimittelforschung Nach der Zulassung

11. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

12. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries

15. Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib

16. Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV

17. Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment

18. Perspektiven

20. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study

28. Arzneimittelprüfung an nicht einwilligungsfähigen Erwachsenen: Kritische Bewertung der neuen gesetzlichen Regelung durch medizinische Ethikkommissionen in Deutschland [Critical evaluation of the new legal regulation of pharmaceutical trials with adults who lack decision-making capacity: a survey of human research ethics committees in Germany]

33. The German competence network ‘Acute and chronic leukemias’

36. Randomized comparison of interferon α and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon α and hydroxyurea

42. Einleitung

43. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)

44. Data from the German-Austrian-Suisse MDS registry (D-A-CH MDS registry): V954

46. Superior CMR-rates with tolerability-adapted imatinib 800 mg vs. 400 mg vs. 400 mg + IFN in CML: The randomized German CML-Study IV: V633

47. Therapy with imatinib in elderly CML patients (≥65 years): Results of the German CML-Study IV: V632

Catalog

Books, media, physical & digital resources